PMID- 15738660
OWN - NLM
STAT- MEDLINE
DCOM- 20050623
LR  - 20220317
IS  - 1076-3279 (Print)
IS  - 1076-3279 (Linking)
VI  - 11
IP  - 1-2
DP  - 2005 Jan-Feb
TI  - Modulation of proliferation and differentiation of human bone marrow stromal 
      cells by fibroblast growth factor 2: potential implications for tissue 
      engineering of tendons and ligaments.
PG  - 41-9
AB  - Bone marrow stromal cells (BMSCs) play a central role in the repair and 
      regeneration of mesenchymal tissues. For tissue engineering of ligaments and 
      tendons, both stimulation of cell proliferation and differentiation with 
      increased expression of essential extracellular matrix proteins and cytoskeletal 
      elements are desirable. This study analyzes the effect of low-dose (3 ng/mL) 
      fibroblast growth factor 2 (FGF-2) and high-dose FGF-2 (30 ng/mL) on 
      proliferation (bromodeoxyuridine content, spectrophotometry), differentiation 
      (transcription of collagen I, collagen III, fibronectin, elastin, alpha-smooth 
      muscle actin, and vimentin, reverse transcription-polymerase chain reaction, and 
      cell density and apoptosis (annexin V, fluorescence-activated cell sorting) of 
      human BMSCs, and compares the results with those of a control group without 
      FGF-2. Low-dose FGF-2 triggered a biphasic BMSC response: on day 7, cell 
      proliferation reached its maximum and was significantly higher compared with the 
      other groups. On days 14 or 28, collagen I, collagen III, fibronectin, and alpha- 
      smooth muscle actin mRNA expression was significantly enhanced in the presence of 
      low-dose FGF-2. In contrast, high-dose FGF-2 did not stimulate differentiation or 
      proliferation. Vimentin mRNA was expressed only in cultures with low-dose and 
      high-dose FGF-2 after 14 and 28 days. Cell density was significantly higher in 
      cultures with low-dose FGF-2 compared with the group with high-dose FGF-2 on days 
      7, 14, and 28. The apoptosis rate remained stable, at a rather high level, in all 
      groups. Microscopic investigation of the cell cultures with low-dose FGF-2 showed 
      more homogeneous, dense, fibroblast-like, spindle-shaped cells with long cell 
      processes compared with cultures with high-dose, or no FGF-2. Low-dose FGF-2 may 
      be useful for tissue engineering of ligaments and tendons by increasing BMSC 
      proliferation and stimulating mRNA expression of specific extracellular matrix 
      proteins and cytoskeletal elements.
FAU - Hankemeier, Stefan
AU  - Hankemeier S
AD  - Trauma Department, Hannover Medical School (MHH), Hannover, Germany. 
      hankemeier.stefan@mh-hannover.de
FAU - Keus, Michaela
AU  - Keus M
FAU - Zeichen, Johannes
AU  - Zeichen J
FAU - Jagodzinski, Michael
AU  - Jagodzinski M
FAU - Barkhausen, Tanja
AU  - Barkhausen T
FAU - Bosch, Ulrich
AU  - Bosch U
FAU - Krettek, Christian
AU  - Krettek C
FAU - Van Griensven, Martijn
AU  - Van Griensven M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tissue Eng
JT  - Tissue engineering
JID - 9505538
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
SB  - IM
MH  - Bone Marrow Cells/*cytology/drug effects/*metabolism
MH  - Cell Proliferation/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Fibroblast Growth Factor 2/*pharmacology
MH  - Humans
MH  - Ligaments
MH  - Stromal Cells/cytology/*drug effects/metabolism
MH  - Tendons
MH  - Tissue Engineering/*methods
EDAT- 2005/03/02 09:00
MHDA- 2005/06/24 09:00
CRDT- 2005/03/02 09:00
PHST- 2005/03/02 09:00 [pubmed]
PHST- 2005/06/24 09:00 [medline]
PHST- 2005/03/02 09:00 [entrez]
AID - 10.1089/ten.2005.11.41 [doi]
PST - ppublish
SO  - Tissue Eng. 2005 Jan-Feb;11(1-2):41-9. doi: 10.1089/ten.2005.11.41.